• UCSBgauchos twitter avatar
    Gauchos lead 1st place LBSU 22-18 with 7:39 left in the second. Sarah Porter leads all scorers with 10 points on 4-4 shooting
    17 min 15 sec ago
  • UCSBgauchos twitter avatar
    There she goes again! Sarah Porter starts the game 3-3 from the field (2-2 on 3s) and has a game-high 8 points. UCSB trails LBSU 13-14
    27 min 59 sec ago
  • UCSBgauchos twitter avatar
    We're 10 minutes away from tipoff at the T-Dome! UCSB (7-9, 2-1) takes on 1st place Long Beach St (12-6, 3-0) looking for a 3rd straight win
    50 min 12 sec ago
  • UCSB_GradPost twitter avatar
    Forging a career in STEM education: The postdoc stage https://t.co/rutLAfXY7O #UCSB #ucsbgradpost
    3 hours 37 min ago
  • ArtsandLectures twitter avatar
    Dance legend Bill T. Jones retired, but he will perform in Story/Time tomorrow night at the @GranadaSB: https://t.co/WjPeUnYgPY
    4 hours 7 min ago
  • ArtsandLectures twitter avatar
    If the interview with @ProfDBrinkley in @SBIndpndnt left you wanting more, the online version is here to help: https://t.co/7xrjH5TFP3
    4 hours 17 min ago
  • UCSB_GradPost twitter avatar
    Optimize your resume with free Jobscan trial https://t.co/uYaESujgQ7 #UCSB #ucsbgradpost
    5 hours 9 min ago
  • UCSB_GradPost twitter avatar
    Author and activist Tim Wise to speak at Campbell Hall on January 25 https://t.co/ceHDtF0Tpu #UCSB #ucsbgradpost
    6 hours 55 min ago
  • UCSB_GradPost twitter avatar
    Black Graduate Student Association to meet January 23 and February 27 https://t.co/uqAuaPCO1t #UCSB #ucsbgradpost
    6 hours 55 min ago

UCSB Researchers Develop Cross-Protective Vaccine

Tuesday, October 21, 2008 - 17:00
Santa Barbara, CA

image.aspx_.jpg

Scientists Douglas Heithoff, left, and Michael Mahan with their new vaccine in a UCSB laboratory.

Doctors have always hoped that scientists might one day create a vaccination that would treat a broad spectrum of maladies. They could only imagine that there might be one vaccine that would protect against, say, 2,500 strains of Salmonella.

And what if that same vaccine could help protect the elderly?

UCSB scientists Douglas Heithoff and Michael Mahan –– along with University of Utah scientists Elena Enioutina, Diana Bareyan, and Raymond Daynes –– believe their recent research suggests that might be possible in the not-too-distant future. In a paper to be published in the November edition of the journal Infection and Immunity, the researchers detail the path to creating a vaccine that confers protection against multiple strains of bacteria.

"Vaccines are great," Mahan said in an interview. "Second to water sanitation, they are the best medical invention of mankind."

The problem with conventional vaccines is that they only protect against a limited number of closely related strains. "That is why flu vaccines need to be administered every year because different flu strains arise every year," Mahan said.

This is what prompted the researchers to begin their quest for a more powerful vaccine that conferred protection against many strains.

The team focused on developing a vaccine against Salmonella, which causes food and blood poisoning –– with over 1.5 million cases in the United States each year.

"It's endemic worldwide," Mahan said. "It's not a carnivore issue –– it's everybody's issue since fruits and vegetables are often the source of infection."

By disarming a "genetic switch," the research team has developed a vaccine that protects against many strains of Salmonella.

The new vaccine stimulates the production of antibodies and immune cells that work together to kill bacteria.

Also, the vaccine does not induce a specific class of inhibitory immune cells that are known to contribute to immune declines in cancer patients. This lack of "immune suppression" is an advantage of the new vaccine over conventional vaccines.

The researchers also showed a link between the immune declines observed in cancer patients and those occurring as part of the normal aging process.

"This may explain why the elderly are more susceptible to infection and why they are more difficult to effectively vaccinate," Mahan said. "Protocols that remove these inhibitory cells may boost vaccine effectiveness in the elderly."

The impact on human health may come in the near term.

The new vaccine is currently being tested in livestock –– the main source of human infection.

"The immunization of livestock can help human health by promoting food safety," Heithoff said. "Of course, the three principal issues for vaccines will always be safety-safety-safety –– and we've put a lot of effort into it."

Funding for this research came from the National Institutes of Health, the United States Department of Agriculture, and The G. Harold & Leila Y. Mathers Foundation.